drug_type
RELEVANT_DRUG
intervention_type
Cell Therapy
drug_description
Autologous TCR-engineered T-cell therapy targeting HPV18-derived peptide presented by HLA-DRB1*09:01; administered as a single infusion to mediate antigen-specific cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a T-cell receptor that recognizes an HPV18-derived peptide presented by HLA-DRB1*09:01 on tumor cells. Antigen engagement triggers TCR signaling, activation, proliferation, cytokine release, and cytotoxic killing (perforin/granzyme and death receptor pathways) of HPV18-positive tumor cells.
drug_name
HRYZ-T101 TCR-T Cell
nct_id_drug_ref
NCT05787535